Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.60
-0.41 (-1.58%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Mineralys Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $48.5. The average 1-year stock price forecast is 89.45% higher than the current stock price, while the lowest is $30 (+17.19%) and the highest is $56 (+118.75%).
Price Target: $48.5 (+89.45%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Mineralys Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 9 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Reiterates $52 | Buy | Reiterates | $52 | +103.12% | Aug 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $49 | Buy | Reiterates | $49 | +91.41% | Aug 12, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $42 → $40 | Buy | Maintains | $42 → $40 | +56.25% | Aug 12, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $55 | Buy | Maintains | $55 | +114.84% | Aug 12, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $54 | Buy | Maintains | $54 | +110.94% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
88.66M
EPS This Year
-4.43
from -2.29
EPS Next Year
-2.50
from -4.43
EPS and Forward PE are based on non-GAAP adjusted numbers.